Last reviewed · How we verify

NCT06575036

Sugammadex Dose Finding Under Two Years Old

Not yet recruiting Phase 2 Last updated 29 August 2024
What this trial tests

Phase 2 trial testing Sugammadex in Neuromuscular Blockade in 33 participants. Not yet recruiting.

Timeline
15 September 2024
Primary endpoint
30 April 2025
31 May 2025

Quick facts

Lead sponsorSang-Hwan Ji
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposetreatment
Enrollment33
Start date15 September 2024
Primary completion30 April 2025
Estimated completion31 May 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Sang-Hwan Ji

Who can join

Under 23 Months, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective dose-finding study of sugammadex for conventional reversal of rocuronium-induced neuromuscular blockade in children under two years of age. This study will explore 50% effective dose and 95% effective dose of sugammadex for reversal of neuromuscular blockade in less than two minutes under biased coin up-and-down method.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sugammadex

Trials testing the same drug.

Other recruiting trials for Neuromuscular Blockade

Currently open trials in the same condition.

Other Sang-Hwan Ji trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06575036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing